The Ministry of Health and Family Welfare has issued a notification under Drugs and Cosmetics Act, 1940 that immediately prohibits the manufacture, sale and distribution of 16 Fixed Dose Combinations (FDCs) deemed irrational or unsafe. The move follows a Supreme Court directive to review all FDCs for therapeutic justification.
Key Developments
- Notification issued under Section 26A of the Act, effective immediately.
- Expert Committee of the Drugs Technical Advisory Board (DTAB) identified 16 FDCs lacking therapeutic justification.
- All State Drug Controllers and enforcement agencies have been instructed to enforce the ban nationwide.
- The official e‑Gazette contains the full list of prohibited combinations.
Important Facts
The prohibited FDCs span several therapeutic categories, including dermatological preparations, analgesic‑antispasmodic mixes, and antibiotic‑based formulations. Examples include Acetyl Salicylic acid + Ethoheptazine, Dicyclomine + Paracetamol + Clidinium Bromide, and Amoxicillin + Serratiopeptidase. The list reflects products that either lack scientific justification or pose potential health risks.
Exam Relevance
Understanding this action is crucial for GS‑3 (Health) and GS‑2 (Polity). It illustrates how the Supreme Court can influence health policy, and how regulatory mechanisms like Section 26A are employed to protect citizens. The case also underscores the importance of rational drug use, a recurring theme in health‑policy questions.
Way Forward
Manufacturers must discontinue production of the listed FDCs and seek approval for any new combinations through the DTAB. State authorities should monitor compliance and report violations. For aspirants, focus on the legal framework governing drug safety, the role of the Supreme Court in policy enforcement, and the broader agenda of promoting rational use of medicines in India.